Kevin R. Sayer Sells 38,464 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM – Get Rating) CEO Kevin R. Sayer sold 38,464 shares of the stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $109.94, for a total transaction of $4,228,732.16. Following the transaction, the chief executive officer now owns 331,337 shares of the company’s stock, valued at approximately $36,427,189.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

DexCom Trading Up 1.4 %

DXCM stock opened at $122.92 on Friday. The company has a market capitalization of $47.50 billion, a PE ratio of 151.29, a P/E/G ratio of 2.69 and a beta of 1.10. DexCom, Inc. has a 12 month low of $66.89 and a 12 month high of $134.76. The firm’s 50-day moving average is $111.06 and its 200 day moving average is $104.51. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.99 and a quick ratio of 1.83.

DexCom (NASDAQ:DXCM – Get Rating) last posted its quarterly earnings results on Thursday, February 9th. The medical device company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.26 by $0.08. The company had revenue of $815.20 million for the quarter, compared to the consensus estimate of $814.52 million. DexCom had a net margin of 11.73% and a return on equity of 16.66%. The firm’s revenue was up 16.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.17 EPS. On average, research analysts anticipate that DexCom, Inc. will post 1.06 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DXCM. Sound Income Strategies LLC boosted its holdings in shares of DexCom by 300.0% in the 3rd quarter. Sound Income Strategies LLC now owns 320 shares of the medical device company’s stock valued at $26,000 after buying an additional 240 shares in the last quarter. Bivin & Associates Inc. boosted its holdings in shares of DexCom by 300.0% in the 2nd quarter. Bivin & Associates Inc. now owns 360 shares of the medical device company’s stock valued at $27,000 after buying an additional 270 shares in the last quarter. Ronald Blue Trust Inc. boosted its holdings in shares of DexCom by 860.5% in the 3rd quarter. Ronald Blue Trust Inc. now owns 365 shares of the medical device company’s stock valued at $27,000 after buying an additional 327 shares in the last quarter. James Investment Research Inc. bought a new stake in shares of DexCom in the 4th quarter valued at about $27,000. Finally, Private Trust Co. NA bought a new stake in shares of DexCom in the 2nd quarter valued at about $29,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of several research reports. Wolfe Research initiated coverage on shares of DexCom in a research report on Thursday, January 26th. They set an “outperform” rating and a $121.00 price objective for the company. Citigroup increased their target price on shares of DexCom from $117.00 to $146.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Stifel Nicolaus increased their target price on shares of DexCom from $120.00 to $130.00 in a research note on Tuesday, December 20th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Friday, February 10th. Finally, Morgan Stanley increased their target price on shares of DexCom from $117.00 to $131.00 and gave the company an “equal weight” rating in a research note on Friday, January 6th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $123.00.

DexCom Company Profile

(Get Rating)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.